Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Robert M. Shavelle"'
Publikováno v:
Developmental Medicine & Child Neurology.
Publikováno v:
Journal of Data Science. 3:371-380
More than 2,000 persons with developmental disability trans- ferred from California institutions into community care during 1993 to early 1996. Using data on 1,878 children and adults moved between April 1, 1993 and March 5, 1996, Strauss, Shavelle,
Publikováno v:
Progress in Transplantation. 31:117-125
Background: Hepatocelluar carcinoma typically occurs with underlying cirrhosis. However roughly 20% of cases arise in a non-cirrhotic liver. There is limited literature that addresses the long-term survival of the narrow subgroup who received transpl
Publikováno v:
Progress in Transplantation. 31:62-71
Background: Hepatocelluar carcinoma, the most common primary liver cancer, has a historically dire prognosis. For hepatic cancer patients with cirrhosis who underwent liver transplantation, we sought to calculate life expectancies both at time of tra
Publikováno v:
The Journal of Spinal Cord Medicine. :1-2
Publikováno v:
Progress in transplantation (Aliso Viejo, Calif.).
Introduction: Non-Alcoholic Steatohepatitis is an increasing reason for liver transplantation in the western world. Knowledge of recipient life expectancy may assist in prudent allocation of a relatively scarce supply of donor livers. Research Questi
Publikováno v:
International Journal of COPD, Vol 2009, Iss default, Pp 137-148 (2009)
Robert M Shavelle1, David R Paculdo1, Scott J Kush1, David M Mannino2, David J Strauss11Life Expectancy Project, San Francisco, CA, USA; 2Pulmonary Epidemiology Research Laboratory, University of Kentucky School of Medicine, Division of Pulmonary and
Externí odkaz:
https://doaj.org/article/b83ccdf2c80b402791943c6bbcdfc569
Publikováno v:
Progress in transplantation (Aliso Viejo, Calif.). 31(4)
Background Alcohol-associated liver disease is the leading cause of liver transplantation in the western world. For these patients we calculated life expectancies both at time of transplant and several years later, stratified by key risk factors, and
Publikováno v:
Multiple Sclerosis and Related Disorders. 68:104219
The median survival time of newly-diagnosed MS patients without severe disabilities is approximately 30-35 years. The prognosis after the onset of severe disability has not been reported. Based on Harding et al.'s 2018 study of the Southeast Wales MS
Autor:
Flora M. Hammond, David J. Strauss, Robert M. Shavelle, Jordan C. Brooks, Cynthia Harrison-Felix
Publikováno v:
Archives of physical medicine and rehabilitation. 103(1)
To update the life expectancy estimates according to age, sex, mobility, and feeding skills reported in the 2015 study of Brooks et al. To examine trends in survival over the past decade.Observational cohort study.Poisson regression and life table an